Nationwide Fund Advisors held its position in shares of Accuray Incorporated (NASDAQ:ARAY) during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 45,296 shares of the medical equipment provider’s stock at the end of the 2nd quarter. Nationwide Fund Advisors owned approximately 0.05% of Accuray worth $215,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the business. TIAA CREF Investment Management LLC grew its holdings in Accuray by 19.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 255,812 shares of the medical equipment provider’s stock valued at $1,215,000 after buying an additional 42,087 shares during the period. Teachers Advisors LLC grew its holdings in Accuray by 83.5% in the 2nd quarter. Teachers Advisors LLC now owns 235,490 shares of the medical equipment provider’s stock valued at $1,119,000 after buying an additional 107,178 shares during the period. Alliancebernstein L.P. grew its holdings in Accuray by 13.3% in the 2nd quarter. Alliancebernstein L.P. now owns 96,891 shares of the medical equipment provider’s stock valued at $460,000 after buying an additional 11,400 shares during the period. Wells Fargo & Company MN grew its holdings in Accuray by 1.5% in the 2nd quarter. Wells Fargo & Company MN now owns 62,059 shares of the medical equipment provider’s stock valued at $295,000 after buying an additional 936 shares during the period. Finally, Cowen Prime Services LLC grew its holdings in Accuray by 1.2% in the 2nd quarter. Cowen Prime Services LLC now owns 189,599 shares of the medical equipment provider’s stock valued at $901,000 after buying an additional 2,200 shares during the period. Institutional investors own 75.47% of the company’s stock.
Shares of Accuray Incorporated (NASDAQ ARAY) opened at $4.60 on Wednesday. The company has a debt-to-equity ratio of 2.44, a quick ratio of 0.92 and a current ratio of 1.48. Accuray Incorporated has a fifty-two week low of $3.60 and a fifty-two week high of $6.00.
Accuray (NASDAQ:ARAY) last issued its earnings results on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.02. Accuray had a negative return on equity of 55.18% and a negative net margin of 7.49%. The business had revenue of $91.00 million during the quarter, compared to analysts’ expectations of $88.26 million. During the same quarter in the previous year, the business earned ($0.12) EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. equities analysts predict that Accuray Incorporated will post -0.18 earnings per share for the current fiscal year.
In other news, COO Kelly Londy sold 99,136 shares of the business’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $4.24, for a total transaction of $420,336.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.90% of the stock is currently owned by insiders.
Several analysts have commented on ARAY shares. Zacks Investment Research cut Accuray from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Cowen and Company restated a “buy” rating and issued a $9.00 price target on shares of Accuray in a report on Friday, October 27th. BidaskClub cut Accuray from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Jefferies Group LLC lowered their price target on Accuray from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 23rd. Finally, BTIG Research restated a “hold” rating on shares of Accuray in a report on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. Accuray presently has a consensus rating of “Hold” and a consensus target price of $6.29.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.